Product Description
AZD3199 was investigated as an inhaled, once-daily uLABA in patients with asthma and COPD.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330041/)
Mechanisms of Action: LAB Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease|Airway Obstruction
Phase 1: Tremor|Abnormalities, Multiple|Healthy Volunteers|Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Evaluation of PK and PD of AZD3199 in dry powder inhalation formulations in patients with asthma | P2 |
Completed |
Asthma |
2012-02-27 |
|
| D0570C00011 | P2 |
Completed |
Asthma |
2012-02-01 |
|
| D0570C00004 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2011-02-01 |
|
| GLAD | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-03-19 |